Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) EBITDA (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed EBITDA for 12 consecutive years, with -$30.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA fell 232.61% year-over-year to -$30.6 million, compared with a TTM value of -$77.8 million through Sep 2025, down 944.7%, and an annual FY2024 reading of -$68.5 million, down 150.49% over the prior year.
  • EBITDA was -$30.6 million for Q3 2025 at Avalo Therapeutics, down from -$20.8 million in the prior quarter.
  • Across five years, EBITDA topped out at $98.5 million in Q2 2024 and bottomed at -$121.3 million in Q1 2024.
  • Average EBITDA over 5 years is -$12.2 million, with a median of -$13.1 million recorded in 2025.
  • Peak annual rise in EBITDA hit 1301.79% in 2024, while the deepest fall reached 1118.38% in 2024.
  • Year by year, EBITDA stood at -$18.0 million in 2021, then soared by 50.71% to -$8.9 million in 2022, then rose by 13.51% to -$7.7 million in 2023, then tumbled by 73.82% to -$13.3 million in 2024, then crashed by 129.51% to -$30.6 million in 2025.
  • Business Quant data shows EBITDA for AVTX at -$30.6 million in Q3 2025, -$20.8 million in Q2 2025, and -$13.1 million in Q1 2025.